

ACC HIGHLIGHTS

2026

ON DEMAND

Developed by:



Program Overview:

This program covered the key clinical trial findings and their implications from ACC 2026. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

- **CHAMPION-AF:** How does left atrial appendage occlusion compare to anticoagulation in AF?
- **SCOUT-HCM:** Extending the benefits of mavacamten to adolescents with obstructive hypertrophic cardiomyopathy.
- **CORALreef Add-On:** How does an oral PCSK9 inhibitor compare to ezetimibe, bempedoic acid, or their combination?
- **Ez-PAVE:** Is achieving a target LDL-C of <1.4 superior to <1.8 in patients with ASCVD?
- **VESALIUS:** Does evolocumab reduce events in patients with diabetes but without known atherosclerosis?

Learning Objectives:

- Review trials and data presented at ACC 2026
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



View OnDemand
www.ccrnmd.com/webcasts

SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,
Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director,
NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University & Mercer University
Atlanta, GA

This program was developed by CCRN and has received unrestricted educational grants from BMS and Merck.

